Bruker Expands Nanoflow Consumables Portfolio for 4D-Proteomics™
February 04 2022 - 6:00AM
Business Wire
Acquires PepSep NanoLC Columns and
Components Company for ease-of-use and robustness
Enters into OEM agreement with IonOpticks
for high-performance nanoLC Aurora columns
- Complementary PepSep and IonOpticks nanocolumns enhance
performance and robustness of timsTOF 4D-Proteomics™
solutions
- PepSep packed nanocolumns for ease of use and robustness
with Bruker CSI emitter
- IonOpticks Aurora columns with integrated emitter tips for
optimized separation power
Bruker Corporation (Nasdaq: BRKR) today announced the
acquisition of PepSep, a Danish company specializing in nanoflow
liquid chromatography (nanoLC) columns, specialty emitters and
components to optimize nanoflow proteomics workflows, which are
extensively used in Bruker’s nanoElute® UHPLC system. Financial
terms of the transaction were not disclosed.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220204005057/en/
PepSep nanoLC column (Photo: Business
Wire)
Founded by Peter Nielsen, PepSep makes unique columns that
minimize post-column eluent mixing. This innovation gives excellent
nanoLC performance with a standard connector, enhancing robust,
routine ease-of-use as the emitter-tip remains in position while
the column is exchanged.
Peter Nielsen said: “It is great to be part of Bruker as it
allows the PepSep team to focus on innovation in separations for
ultra-high throughput proteomics on the timsTOF platform. Matching
separations technology that is ultra-robust and delivers the best
sensitivity for high-speed TIMS/PASEF detection, with the ease of
use of non-integrated tips was important, and we now can continue
to develop chemistries to drive performance enhancements for
4D-Proteomics and 4D-Lipidomics applications.”
Dr. Brett Phinney, Proteomics Core Director at the UC Davis
Genome Center, has been using PepSep products for about a year, and
stated: “I’m happy to use PepSep columns in my laboratory. They are
better than what I can make myself, and my short gradient results
are impressive. These are by far the best columns I’ve used to
date.”
Bruker is also pleased to announce an OEM partnership and
agreement with IonOpticks Pty Ltd in Melbourne, Australia.
IonOpticks was founded by Associate Professor Andrew Webb from The
Walter and Eliza Hall Institute (WEHI) and his colleagues Drs.
Jarrod Sandow and Guiseppe Infusini. IonOpticks offers Aurora
columns with nanoZero® UHPLC fitting and integrated packed emitter
tips that result in excellent peak shapes and maximized separation
power. Andrew Webb and team created a unique emitter design with no
post-column dead volume and the user friendly ‘plug and play’
nanoZero connection. IonOpticks will now produce the Bruker Focus
series nanoLC columns with identical performance as the Aurora
series.
Dr. Andrew Webb commented: “Ultra-high throughput proteomics,
where we analyze large patient cohorts, will allow us to compare
signatures not just across disease states but to truly understand
disease in the context of health. My WEHI lab was an early adopter
of the timsTOF technology which allowed us to run faster methods,
and the Aurora columns deliver the ultra-high sensitivity with
unmatched robustness required to run 50 SPD (samples per day)
methods.”
Dr. Michael Krawitzky, Bruker’s Product Manager for LC-MS
consumables, stated: “The addition of PepSep’s column portfolio
combined with the IonOpticks high-performance pulled tip columns
provide our timsTOF customers more nanoLC choices to advance their
applications. Our timsTOF customers expect excellent sensitivity
and robustness, which this combined Bruker and OEM nanoLC portfolio
will add."
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity, and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220204005057/en/
Media: Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investors: Justin Ward Sr. Director, Bruker Investor
Relations T: +1 (978) 663-3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024